Milestone Deadline Clause Samples

The Milestone Deadline clause sets specific dates by which certain project milestones must be completed. It typically outlines the key deliverables or phases of a project and assigns a deadline to each, ensuring that progress can be tracked and managed effectively. By establishing clear timeframes for each stage, this clause helps prevent delays, keeps all parties accountable, and supports the timely completion of the overall project.
POPULAR SAMPLE Copied 1 times
Milestone Deadline. 1. The Company shall agree to the terms and form of a transaction support agreement with one or more lenders in form and substance mutually satisfactory to the Collateral Agent and the Company, (the “Transaction Support Agreement”). August 22, 2023 or such later date as is agreed to by the Collateral Agent in its sole discretion 2. Subject to any necessary shareholder approvals, the parties shall have executed and delivered, or reached agreement on substantially final versions of, the definitive documentation with respect to the August 31, 2023 or such later date as is agreed to by the Collateral Agent in its sole discretion ​ ​ 3. The Company shall have closed the transactions specified by the Transaction Support Agreement. September 15, 2023 or such later date as is agreed to by the Collateral Agent in its sole discretion ​ 3. Section 6.8(b) of the Note Purchase Agreement is hereby deleted in its entirety and replaced with: “Minimum Consolidated Liquidity. Company shall not permit Consolidated Liquidity to be less than: 1.prior to May 13, 2021, $9,000,000;
View Source
Milestone Deadline. Completion Condition: (Where applicable) Connection Agreement Effective Date [ • ] On acceptance of a Connection Offer. Consents Issue Date (as defined in the Connection Agreement) [ • ] On receipt by the TSO of a grant of planning permission for the development, the MIC bond, insurances and relevant consents. Connection works Completion Date (end of Construction Period) [ • ] On receipt by the TSO of all testing certificates, safety file and as-built drawings after precomissioning handover is complete. Energisation Date (As defined in the Connection Agreement) [ • ] When the TSO issues an Energisation Instruction Operational Date (As defined in the Connection Agreement) [ • ] On receipt of Operational Certificate. Go-Live Date (As defined in this Agreement) [ • ] As defined in this Agreement 1 Either Party may notify the other Party following the occurrence or discovery of any item or event which the notifying Party acting in good faith considers to be a dispute under this Agreement.
View SourceView Similar (2)
Milestone Deadline. 1. 1. The Company shall have entered into as engagemententer into a transaction support agreement, with one or more lenders in form and substance mutually satisfactory to the Collateral Agent (including with respect to the scope of the engagement and the compensation for such engagement) in its sole discretion, with an investment banking professional services firm satisfactory to Collateral Agent in its sole discretion (it being understood and agreed that the banking professional services firms set forth on Exhibit 5.18 shall be deemed to be satisfactory to Collateral Agent) (the “Investment Bank”) in connection with a repayment of all of the Obligations under the Notes (the “Refinancing”)and the Company, (the “Transaction Support Agreement”). August 10, 2022The date that is 30 days after the Fourth Amendment Effective Date
View Source
Milestone Deadline. 1. The Debtors shall file (i) the Plan (as defined in the TSA), (ii) the Disclosure Statement (as defined in the TSA), (iii) a motion seeking approval of the DIP Note Documents (to be requested to be heard on shortened time), and (iv) any “first day” motions, each of which shall be in form and substance acceptable to Purchaser. No later than the PetitionDate 2. The Bankruptcy Court shall have entered the Interim Order approving the DIP Note Documents, which order shall be in form and substance acceptable to Purchaser. No later than three (3)calendar days after thePetition Date 3. The Bankruptcy Court shall have entered the FinalOrder approving the DIP Note Documents, which ordershall be in form and substance acceptable to Purchaser. No later than November 15, 2023 4. The Bankruptcy Court shall have held a hearing (the “Confirmation Hearing”) and entered an order confirming the Plan and approving the Disclosure Statement (the “Confirmation Order”), which Confirmation Order shall be in form and substanceacceptable to Purchaser. No later than November 15, 2023 5. The Plan shall become effective (the “Plan EffectiveDate”). No later than November 30, 2023 6. Company shall have delivered the Approved Budgetto Collateral Agent. On the Closing Date and oneach Friday of every othercalendar week thereafter 7. Company shall have delivered a Variance Report toCollateral Agent. On each Variance ReportDate ​ ​
View Source
Milestone Deadline. 1 Substantial Completion and Temporary Certificate(s) of Occupancy Floors 28-34 (marketing floor designations), excluding Hoist Run Units December 15, 2021 2 Substantial Completion and Temporary Certificate of Occupancy Floors 27 and 35-39 (marketing floor designations), excluding Hoist Run Units February 28, 2022
View Source
Milestone Deadline. Paragraph (c) of Section 7.6 of the Forbearance Agreement is hereby amended by deleting the date "July 31, 2001" appearing in such paragraph (c) and inserting in place thereof the following phrase: "11:59 p.m., Boston time, on August 15, 2001"
View Source

Related to Milestone Deadline

  • Milestone Event Milestone Payment [***] [***]

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Milestone Schedule Please state the status and progress of each Milestone and identify any completed Milestone(s) for the previous calendar quarter.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Development Milestone Payments TriSalus shall pay (or cause to be paid) to Dynavax, in accordance with and subject to the terms of this Section 2.3, Section 2.4 and Section 6.4 (each such milestone, a “Development Milestone”, and each payment in respect thereof, a “Development Milestone Payment”): (i) Upon the successful completion by a Milestone Obligor after the Closing of a [**] study with respect to a Product using PEDD, a payment of [**] US Dollars ($[**]), with such Development Milestone Payment being payable only once (for purposes of the foregoing, successful completion means completion of such study in accordance with the plan for such study); (ii) For the first patient Dosed by a Milestone Obligor in each Phase 1 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iii) For the first patient Dosed by a Milestone Obligor in each Phase 2 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iv) For each Phase 2 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 2 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 2 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (v) For each Phase 3 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 3 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 3 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (vi) Upon receipt by a Milestone Obligor of each Regulatory Approval for any Product for any Indication in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (vii) Upon receipt by a Milestone Obligor for each Regulatory Approval of any Product for any Indication in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (viii) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vi) for receipt of such Regulatory Approval), regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; and (ix) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vii) for receipt of such Regulatory Approval), regardless ​ of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval.